8-KOther EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Dec 20, 2010)

Filed December 20, 2010For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced positive results from two key clinical trials for its investigational drug, VEGF Trap-Eye (aflibercept ophthalmic solution). The press release, filed on December 20, 2010, detailed positive outcomes from a Phase 3 study in Central Retinal Vein Occlusion (CRVO) and a Phase 2 study in Diabetic Macular Edema (DME). These trial results are significant for investors as they represent advancements in the development of potential treatments for serious retinal conditions, potentially expanding Regeneron's product pipeline and future revenue streams. The drug was generally well-tolerated in both studies, with specific details provided regarding serious adverse events, indicating a favorable safety profile thus far.

Key Highlights

  • 1Positive results announced for VEGF Trap-Eye in Phase 3 study for Central Retinal Vein Occlusion (CRVO).
  • 2Positive results announced for VEGF Trap-Eye in Phase 2 study for Diabetic Macular Edema (DME).
  • 3VEGF Trap-Eye demonstrated a generally well-tolerated safety profile in both studies.
  • 4No ocular drug-related serious adverse events reported in the CRVO Phase 3 study.
  • 5One non-ocular drug-related serious adverse event reported in the second six months of the CRVO Phase 3 study.
  • 6The company is advancing its pipeline with promising late-stage trial data.
  • 7These results could lead to new treatment options for significant ophthalmic diseases.

Frequently Asked Questions

Regeneron announced positive results from a Phase 3 study in Central Retinal Vein Occlusion (CRVO) and a Phase 2 study in Diabetic Macular Edema (DME) for its investigational drug, VEGF Trap-Eye. The drug was generally well-tolerated and showed promising outcomes in treating these retinal conditions.

VEGF Trap-Eye, also known as aflibercept ophthalmic solution, is an investigational drug being developed by Regeneron for the treatment of various eye diseases. It targets vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth and leakage in the eye.

These positive trial results are significant as they advance VEGF Trap-Eye through the clinical development process. Success in these indications could lead to new product approvals, expanding Regeneron's portfolio and revenue potential for treating significant ophthalmic conditions.

VEGF Trap-Eye was generally well-tolerated. In the CRVO Phase 3 study, there were no ocular drug-related serious adverse events. Regarding non-ocular serious adverse events judged to be drug-related, there were none during the first six months and one in the second six months of the study.